CONCLUSIONS
Sports federations that have introduced blood tests actually
have a powerful tool to follow all athletes potentially
misusing rHuEPO or blood transfusion. The anti-doping tests
need to be focused mainly on those demonstrating abnormal
blood data. This targeting will also enable the federations to
determine the prevalence of doping methods before any
validated anti-doping test is introduced on the market. This
was the way in which it was found out that haemoglobin
based oxygen carrier (HBOC) misuse was not a major
problem.